BridgeBio Pharma's infigratinib for achondroplasia demonstrated significant benefits beyond height gain, including improvements in sleep apnea, ear infections, and body composition. This positive clinical data strengthens the drug's commercial potential and supports the company's upcoming FDA and EMA applications, positioning it as a potentially transformative treatment.
BridgeBio Pharma announced positive 52-week clinical data for its oral infigratinib in treating achondroplasia, showing benefits in sleep apnea, otitis media, and body composition, in addition to growth. This is a significant development as it broadens the drug's therapeutic profile, making it more attractive to patients, physicians, and regulators. The company anticipates a U.S. launch in mid-2027 and an EU submission in Q4 2026, indicating a clear path to market. For traders, this data de-risks the drug's approval process and enhances its long-term revenue potential, potentially leading to increased investor confidence and upward pressure on BBIO's stock price, especially given the analyst consensus and momentum score.